Date of Award

Spring 1996

Document Type



Life & Environmental Sciences

First Advisor

John Christenson

Second Advisor

Guido Bugni

Third Advisor

Joan Stottlemyer


A study at Deaconess Research Institute was initiated to determine the contribution of low-dose Methotrexate to the development of osteopenia. Findings are based upon analysis of Dual Energy X-ray Absorptiometry (DEXA) scans for bone density and bone mass. Scans were performed 18 to 24 mo apart for 5 of 11 patients currently undergoing low-dose Methotrexate therapy for the treatment of rheumatoid arthritis. The results suggest there is no correlation between low-dosage Methotrexate and osteopenia/osteoporosis and that therapeutic doses seem to pose little threat of significant bone loss.